Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib

While significant progress has been made in the treatment of acute myeloid leukemia (AML), not all patients can be cured. Mutated in about 1/3 of de novo AML, the FLT3 receptor tyrosine kinase is an attractive target for drug development, activating mutations of the FLT3 map to the juxtamembrane dom...

Descripción completa

Detalles Bibliográficos
Autores principales: Uras, Iris Z., Maurer, Barbara, Nebenfuehr, Sofie, Zojer, Markus, Valent, Peter, Sexl, Veronika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321303/
https://www.ncbi.nlm.nih.gov/pubmed/30544932
http://dx.doi.org/10.3390/ijms19123987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321303/
https://www.ncbi.nlm.nih.gov/pubmed/30544932
http://dx.doi.org/10.3390/ijms19123987

Ejemplares similares